News
Novo Nordisk's Wegovy Showdown: Navigating Market Pressures and Potential Layoffs
Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job cuts. Despite lucrative past sales, Novo warns of slower growth due to rival generics and compounding pharmacies,
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.
Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...
On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...
Novo Nordisk is misunderstood by the market, creating a rare asymmetric value opportunity. Read why I rate NVO stock a Buy ...
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback